Skip to content

AMES + Brain Stimulation

AMES + Brain Stimulation: Treatment for Profound Plegia in Stroke

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01169181
Acronym
AMES
Enrollment
6
Registered
2010-07-26
Start date
2010-07-31
Completion date
2019-12-31
Last updated
2016-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Accident, Plegia, Stroke

Keywords

Stroke, Cerebrovascular Accident, Plegia, Upper Extremity, rTMS, tDCS

Brief summary

The procedure involves: (1) assisted hand movement by a mechanical device, (2) mechanical vibration applied to the surface of the forearm, and (3) stimulation of the brain with either transcranial magnetic stimulation (TMS) or transcortical direct current stimulation (DCS). These 3 components of the procedure are carried out simultaneously. Each subject will be evaluated pre- and post-treatment with several clinical tests of functional movement. The hypotheses of this project are that the AMES+rTMS and AMES+tDCS procedures are safe and will enable most of the stroke patients to recover finger extension.

Detailed description

This protocol is designed to investigate the safety and efficacy of a procedure for treating chronic (\>1 year post) stroke patients who still cannot move the hand affected by the stroke. The treatment involves: (1) assisted hand movement by a mechanical device, (2) mechanical vibration applied to the surface of the forearm, and (3) stimulation of the brain with either transcranial magnetic stimulation (TMS) or transcortical direct current stimulation (DCS). Subjects receiving TMS during treatment are expected to respond more fully (i.e., increased volitional EMG) in the treated hand compared to those receiving DCS.

Interventions

DEVICEAMES + brain stimulation

Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
AMES Technology
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Stroke occurring ≥12 months before enrollment * Hemispheric stroke (ischemic or hemorrhagic), cortical or subcortical * Residual upper-extremity weakness without the ability to activate volitionally extensor digitorum (no volitional EMG in the long finger extensor muscle)independently * Age 18-75 years old

Exclusion criteria

* Significant upper-extremity proprioceptive deficit (\<70% correct detection of the direction of passive finger movement, with eyes closed) * Cortical stroke involving the primary motor cortex * Epilepsy not controlled by medication * Botox injections 5 months before or during enrollment; use of intrathecal Baclofen * Residual pain in the tested arm * Significant neglect involving the affected limb (NIHSS 2 on the extinction and attention items) * Exercise intolerant * Uncontrolled hypertension or angina * Cognitive or behavioral inability to follow instructions * Current abuse of alcohol or drugs * Terminal illness with anticipated survival of \<12 months * Severe apraxia; inability to understand oral directions in English; or inability to communicate adequately with study personnel * Circumference of arm incompatible with the AMES device (checked by placing the limb in the device) * Contractures, decreased range of motion, or skin condition preventing tolerance of the AMES muscle vibrators * Spinal cord injury, arthritis, or fractures of affected limbs resulting in loss of range of motion * In the tested arm, peripheral nerve injury or neuropathy resulting in significant motor or sensory loss * Pathological neurological/physical condition other than stroke that impairs the function of the impaired arm or that produces pain in the impaired arm * Implanted device (e.g., cardiac pacemaker, Baclofen pump) the operation of which might be adversely affected by the brain stimulation * Previous vascular surgery on the blood vessels of the brain or heart or heart valve surgery * Female and pregnant

Design outcomes

Primary

MeasureTime frameDescription
Maximum volitional EMG in the extensor digitorum and the finger flexorsFollowing each treatment with the AMES deviceEMG intensity will be measured during maximal efforts at hand opening and closing at the end of each treatment session. The averages of 3 attempted openings and 3 closings will be determined and recorded.

Secondary

MeasureTime frameDescription
Chedoke-McMaster Stroke AssessmentBefore the first treatment session, and again after the last treatment session.A validated assessment tool for evaluating the severity of physical impairment in adult stroke survivors.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026